Photo via Unsplash
A bioelectricity startup has raised $95 million in funding to develop what could become the first non-pharmaceutical treatment for hypertension. The device targets the renal nerves using precisely calibrated electrical pulses, offering patients an alternative to lifelong medication.
High blood pressure affects over 1.3 billion people worldwide and remains the leading modifiable risk factor for cardiovascular disease. Despite decades of pharmaceutical innovation, roughly half of patients with hypertension fail to achieve adequate blood pressure control, even with multiple medications. The startup’s approach draws on research showing that overactive renal sympathetic nerves contribute significantly to treatment-resistant hypertension. By delivering targeted electrical signals to modulate nerve activity, the device aims to restore normal blood pressure regulation without the side effects associated with antihypertensive drugs.
Early clinical trials have shown promising results, with patients experiencing significant reductions in both systolic and diastolic blood pressure after a single procedure. The funding round will support a pivotal Phase III trial designed to support FDA approval.
Why the Kidney Is the Right Target
The kidneys are not passive filters. They are active participants in blood pressure regulation, constantly communicating with the brain via a dense network of sympathetic nerve fibers that run alongside the renal arteries. These renal nerves serve two functions: efferent fibers carry signals from the brain to the kidney, increasing sodium retention and renin secretion in response to perceived stress; afferent fibers carry sensory information back to the brain, influencing central sympathetic tone across the entire cardiovascular system.
In patients with treatment-resistant hypertension, this bidirectional signaling loop runs chronically hot. Elevated renal sympathetic nerve activity (RSNA) drives the kidney to retain more sodium and water, increasing blood volume and raising pressure. At the same time, the afferent signals from an overworked kidney amplify central sympathetic drive, pushing heart rate up and constricting blood vessels throughout the body. The result is a reinforcing feedback loop that pharmaceutical agents—targeting individual receptors or enzymes—struggle to break comprehensively.
The idea of disrupting renal nerve activity to treat hypertension is not new. Surgical sympathectomy—physically severing sympathetic nerve trunks—was practiced in the mid-twentieth century and produced dramatic blood pressure reductions, but at the cost of debilitating side effects including severe orthostatic hypotension and impaired bladder function. The modern bioelectronic approach aims to achieve nerve modulation with far greater precision: not ablating the nerve permanently but tuning its activity, and doing so with a specificity that surgery could never deliver.
From Ablation to Modulation: The Shift in Renal Denervation
The field of catheter-based renal denervation gained significant momentum in the early 2010s following the Symplicity HTN-1 and HTN-2 trials, which reported blood pressure reductions of 20-30 mmHg using radiofrequency energy to ablate renal nerves. The subsequent Symplicity HTN-3 trial, the first sham-controlled study, produced a more sobering result: the ablation arm did not significantly outperform the sham procedure. The setback sent the field back to the drawing board, prompting a reexamination of both technique and technology.
What emerged from that reassessment was a recognition that radiofrequency ablation—which destroys a swath of tissue indiscriminately—is a blunt instrument for a problem that demands precision. Nerve fibers around the renal artery are not uniformly distributed; they cluster in distinct locations and vary in their functional importance. Incomplete or poorly targeted ablations leave overactive fibers intact. Overly aggressive treatment damages the artery wall and surrounding structures.
The bioelectronic approach being developed by this startup represents a conceptual leap: instead of burning nerve tissue, the device delivers electrical pulses tuned to interfere with or modulate nerve conduction. This could mean high-frequency electrical nerve block—where rapid pulses prevent action potential propagation without destroying the fiber—or more nuanced waveforms that selectively suppress efferent signaling while preserving afferent feedback. The distinction matters enormously. Preserving afferent sensing allows the kidneys to continue reporting their status to the brain, maintaining the reflexes that protect against sudden blood pressure drops during changes in posture or hydration.
The Road to Approval and the Patient Population That Needs It
The $95 million funding round will anchor a pivotal Phase III trial, the scale and design of which will likely mirror the lessons of Symplicity HTN-3. Crucially, that means a rigorous sham-controlled design in which patients in the control arm undergo the catheterization procedure but receive no electrical treatment—blinding both patient and physician to the intervention. This level of blinding is difficult and expensive to execute in a device trial, but regulatory agencies now require it for hypertension devices given the well-documented placebo effect on blood pressure measurement.
The target patient population—those with treatment-resistant hypertension already on multiple medications—represents millions of people globally for whom current options are exhausted or intolerable. ACE inhibitors cause persistent cough in a meaningful fraction of users. Aldosterone antagonists carry risks of hyperkalemia, particularly dangerous in patients with impaired kidney function. Beta-blockers blunt exercise capacity and are poorly tolerated by active patients. Diuretics demand careful monitoring and dietary compliance. For patients who have cycled through combinations of these agents without achieving control, a single interventional procedure that resets sympathetic tone carries enormous appeal.
Beyond hypertension, the platform has potential implications for heart failure, chronic kidney disease, and metabolic syndrome—conditions that share dysregulated autonomic nervous system activity as a common thread. Renal nerve modulation that reduces sympathetic overdrive could simultaneously improve cardiac output, slow kidney disease progression, and improve insulin sensitivity. The $95 million bet is ultimately not just on a device for blood pressure—it is on a new category of autonomic medicine, one that treats the electrical wiring of the body rather than the chemical messages it carries.
What makes this moment particularly ripe is the convergence of miniaturized electronics, improved catheter navigation systems, and a far richer understanding of renal nerve anatomy than existed a decade ago. High-resolution imaging now allows electrophysiologists to map nerve fiber locations before delivering energy, and closed-loop feedback systems can confirm adequate modulation in real time. The procedural failures of first-generation renal denervation were partly failures of information; the devices didn’t know whether they were hitting the right fibers. The next generation knows—and that knowledge is measured in electrical signals, precisely where bioelectronic medicine is most at home.
Sources and Further Reading
- Bhatt, D.L. et al. (2014). A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine, 370.
- Mahfoud, F. et al. (2022). Catheter-based renal denervation in patients with resistant hypertension. The Lancet, 401.
- Bisognano, J.D. et al. (2011). Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. Journal of the American College of Cardiology, 58(7).